SENSITIVE TO THE EFFECTS OF ENVIRONMENTAL FACTORS miR-638 AND COMMON DISEASES

© A.N. Kucher

Research Institute of Medical Genetics, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Cite this article as: Kucher AN. Sensitive to the effects of environmental factors miR-638 and common diseases. Ecological Genetics. 2019;17(3):99-110. https://doi.org/10.17816/ecogen17399-110.

The review provides information on environmental factors affecting the level of miR-638 in humans, potential target genes of this micro-RNA (according to “TargetScanHuman”), diseases and metabolic pathways which potentially regulated miR-638, as well as clinical and experimental data confirming the involvement of miR-638 in the developing a wide range of multifactorial diseases. The data presented in the review expand the understanding of the pathogenesis of various diseases of a multifactorial nature and determine new strategies for studying gene-environment interactions that are important for the formation of health.

Keywords: microRNA; miR-638; common diseases.

Research suggests that the development of widespread diseases is promoted by various exogenous factors, the effects of which can be depending on the genetic features of individuals. Among these genetic factors, that contribute to risk of diseases the structural diversity of the genome has been frequently studied. However, in recent years research on the epigenetic components of multifactorial diseases has also been conducted [1–5]. Changes in the spectrum and level of microRNA, as well as epigenetic modifications (including DNA methylation), are considered important components of a disease’s pathophysiology, including as intermediaries of the unfavorable environmental factors that contribute to disease development [6–9]. In this context, miR-638 is of interest since it is sensitive to the exposure of different biotic and abiotic agents. The degree of change to miR-638 depends on the affecting agents, the duration of the effect, and the types of cells involved [10–17]. Low levels of miR-638 were detected in individuals exposed to chronic benzene poisoning, compared with individuals not in contact with the substance (control group) and those who had short-term contact with the substance. Concurrently, individuals experiencing short-term exposure to benzene had higher levels of miR-638 than had those in the control group [13]. Another research also registered a considerable increase in miR-638 among workers exposed to polycyclic aromatic hydrocarbons [11]. An increase in miR-638 levels was registered.
during cell treatment with benzo(a)pyrene (in a dose-dependent manner) [11], whereas bidirectional effects were detected following exposure to inorganic arsenic (a decrease in the level of this microRNA in the endothelial cells of the umbilical vein, an increase in the white blood cell culture) [15, 18]. It is assumed that this microRNA can be employed as a biomarker for the assessment of the effects of unfavorable environmental factors in the workplace [15].

A stimulating impact on miR-638 expression was determined for a number of viruses, including the enterovirus (EV71) [16] and the chikungunya disease virus (CHIKV) [12]. However, Liu et al. [14] demonstrated that the hepatitis C virus inhibited the expression of this microRNA in the cells of human hepatoma. Furthermore, miR-638 can affect the degree of infection and, in particular, can reduce the transcription of the hepatitis B virus [19, 20]. Additionally, miR-638 is sensitive to oxidative stress [21] and temperature conditions (its level is reduced at high temperatures) [22]. Narahallobh et al. [22] assigned microRNA (including miR-638) an important regulatory role in the acute response to modified environmental conditions, which stipulates remodeling in cells and tissues. Because of the specificity in the function of microRNA, miR-638 controls the expression of many genes at a translational level. Accordingly, changes in the expression of this microRNA (including under the effect of biotic and abiotic environmental factors) can impact a range of metabolic pathways.

miR-638 is expressed in multiple tissues including brain, kidney, skin, and fat, among others. It is also expressed in more than 800 cell lines (including different types of blood cells) and in more than 500 types of tumor across multiple organs [23, 24]. A high level of miR-628 expression can be explained by the fact that it is involved in the regulation of the cell cycle [25–27].

The MIR638 gene is localized in chromosome 19p13.2, in an intron of the DNM2 gene (dynamin 2); polymorphic variants (primarily single nucleotide replacements) are registered in the gene of this microRNA, but they are all low polymorphic [28, 29].

This review presents data on the possible pathogenetic effects of miR-638 that are sensitive to environmental factors. For this purpose, 1) an analysis of the functional significance of genes that can be regulated by miR-638 was performed and 2) data sourced from scientific publications on the involvement of miR-638 in the pathogenesis of different diseases was integrated.

Target genes of miR-638, their involvement in metabolic pathways, and links with diseases

Genes that are regulated by miR-638 were identified using TargetScanHuman (version 7.2; updated March 2018) [30, 31]. In total, miR-638 demonstrated potential binding sites for 1,877 transcripts (a total of 2,136 binding sites). Thus, at a translational level, miR-638 can control the expression of roughly 2,000 genes.

To determine the extent to which sets of genes having target sites for miR-638 are random, enriched gene sets among genes associated with different categories of pathologies/groups of pathology (as per the Disease database) and metabolic pathways (as per the KEGG Pathway Database) were assessed using the analytical internet resource Web-Gestalt [32, 33]. Data were obtained on the basis of the hypergeometric test. The level of statistical significance was determined using allowance, as per the Benjamini–Hochberg method. As a result of the analysis of genes potentially targeting miR-638, 533 diseases/groups of pathologies and 62 metabolic pathways were detected, with a statistical significance level of \( p < 0.05 \).

Table 1 provides examples of such diseases and metabolic pathways, the number of genes of reference genes in the category, and the statistical parameters that characterize an excess of representation for miR-638 target genes.

Genes that are potentially regulated by miR-638 are presented as statistically significantly excessive for a wide range of diseases of the central nervous system and cardiovascular system, among oncological diseases, inflammatory and autoimmune pathologies, involved in the regulation of cell cycles, and in supporting genome stability, and are indicated as being involved in metabolic pathways and disorders, in which functioning can be a reason for these pathologies. The number of metabolic pathways in which the target genes of miR-638 are represented in excess directly indicates pathological conditions (e.g., oncologic disease, amyotrophic lateral sclerosis, renal cell cancer, and small-cell lung cancer). The causes of the above diseases include smoking, unfavorable environmental exposure (pollutants and mutagens), and viruses, among others. Additionally, miR-638 is also sensitive to exposure to environmental factors at the methylation level of CpG sites, and its expression [10–13].

Genes that are studied in the context of cardiovascular disease pathogenesis are potentially regulated by miR-638. This microRNA regulates the expression of genes that are involved in blood coagulation \((F8, F13A1,\) and \(F10)\), the metabolism of fats and carbohydrates \((SLC2A9, LDLR,\) and \(FADS1)\), encoding calcium \((CACNA1C)\) and potassium \((KCNDC3, KCNJ5)\) channels, cardiotoxin \((CTF1)\), methylenetetrahydrofolate reductase \((MTHFR)\), and vascular endothelial growth factor \((VEGFA)\). Additionally, miR-638 regulates the expression of oncogenes \((RAN, FEV, USP6, PIM1,\) and \(RAB36)\), cell cycle genes \((CDKN2B\) and \(CCND1)\), and the \(BRCA1\) gene. Moreover, miR-638 controls proteins involved in repair processes \((RFC3, RFC2, MSH3,\) and \(RPA1)\). Thus, on the basis of this analytical approach, it appears that changes in the level of miR-638 can result in disorders of different metabolic pathways that are im-
Examples of disease categories (as per database Disease) and metabolic pathways (as per the KEGG Pathway Database) for which genes that are potentially regulated by miR638 were determined.

| Diseases (groups of diseases)/metabolic path-ways | ID       | C   | O   | E    | R     | adjP       |
|--------------------------------------------------|----------|-----|-----|------|--------|------------|
| Diseases in which the largest number of genes are potentially regulated by miR 638 |          |     |     |      |        |            |
| Nervous System Diseases                          | PA445093 | 694 | 77  | 29.13| 2.64   | 1.86 \cdot 10^{-11} |
| Mental Disorders                                  | PA447208 | 564 | 62  | 23.67| 2.62   | 5.25 \cdot 10^{-9}  |
| Congenital Abnormalities                          | PA443223 | 643 | 67  | 26.99| 2.48   | 5.64 \cdot 10^{-9}  |
| Brain Diseases                                    | PA443553 | 411 | 50  | 17.25| 2.90   | 7.70 \cdot 10^{-9}  |
| HI virus                                          | PA447230 | 755 | 73  | 31.69| 2.30   | 1.37 \cdot 10^{-8}  |
| Central Nervous System Diseases                  | PA443657 | 438 | 51  | 18.38| 2.77   | 1.62 \cdot 10^{-8}  |
| Cardiovascular Diseases                          | PA443635 | 425 | 48  | 17.84| 2.69   | 1.40 \cdot 10^{-7}  |
| Genetic Predisposition to Diseases               | PA446882 | 808 | 73  | 33.91| 2.15   | 1.77 \cdot 10^{-7}  |
| Musculoskeletal Diseases                         | PA445001 | 462 | 50  | 19.39| 2.58   | 2.10 \cdot 10^{-7}  |
| Epilepsy                                          | PA444065 | 201 | 30  | 8.44 | 3.56   | 2.53 \cdot 10^{-7}  |
| Diseases of the cardiovascular system            |          |     |     |      |        |            |
| Heart Diseases                                    | PA444368 | 366 | 41  | 15.36| 2.67   | 1.19 \cdot 10^{-6}  |
| Hypertension                                      | PA444552 | 227 | 28  | 9.53 | 2.94   | 1.63 \cdot 10^{-5}  |
| Atherosclerosis                                   | PA443425 | 214 | 26  | 8.98 | 2.89   | 4.67 \cdot 10^{-5}  |
| Arterial Occlusive Diseases                       | PA443423 | 219 | 26  | 9.19 | 2.83   | 6.60 \cdot 10^{-5}  |
| Myocardial Ischemia                               | PA446459 | 261 | 29  | 10.95| 2.65   | 6.65 \cdot 10^{-5}  |
| Coronary Artery Disease                           | PA443796 | 254 | 28  | 10.66| 2.63   | 0.0001                |
| Aortic Diseases                                   | PA443393 | 64  | 11  | 2.69 | 4.10   | 0.0009                |
| Cardiovascular Abnormalities                      | PA446717 | 164 | 17  | 6.88 | 2.47   | 0.0050                |
| Brain Ischemia                                    | PA443671 | 09  | 13  | 4.57 | 2.84   | 0.0056                |
| Arrhythmias, Cardiac                              | PA443421 | 107 | 12  | 4.49 | 2.67   | 0.0116                |
| Stroke                                            | PA447054 | 235 | 20  | 9.86 | 2.03   | 0.0132                |
| Myocardial Infarction                             | PA445019 | 242 | 20  | 10.16| 1.97   | 0.0167                |
| Cerebellar Diseases                               | PA443660 | 133 | 13  | 5.58 | 2.33   | 0.0194                |
| Heart Block                                       | PA444366 | 49  | 7   | 2.06 | 3.40   | 0.0199                |
| Essential Hypertension                            | PA447288 | 120 | 12  | 5.04 | 2.38   | 0.0212                |
| Cardiomegaly                                      | PA444369 | 120 | 12  | 5.04 | 2.38   | 0.0212                |
| Aortic Aneurysm                                   | PA446510 | 39  | 6   | 1.64 | 3.67   | 0.0233                |
| Carotid Artery Diseases                           | PA443636 | 81  | 9   | 3.40 | 2.65   | 0.0272                |
| Atrial Fibrillation                               | PA443459 | 67  | 8   | 2.81 | 2.85   | 0.0274                |
| Aortic Aneurysm                                   | PA443394 | 19  | 4   | 0.80 | 5.02   | 0.0280                |
| Infarction                                        | PA444613 | 236 | 18  | 9.90 | 1.82   | 0.0370                |
| Heart Arrest                                      | 60       | 7   | 2.52| 2.78 | 0.0396 |
| Oncological diseases                              |          |     |     |      |        |            |
| Cancer or Viral Infections                        | PA128407012 | 951 | 79  | 39.91| 1.98   | 8.31 \cdot 10^{-7}  |
| Liver Neoplasms                                   | PA444804 | 242 | 30  | 10.16| 2.95   | 7.38 \cdot 10^{-6}  |
| Carcinoma, Hepatocellular                        | PA444447 | 208 | 26  | 8.73 | 2.98   | 2.91 \cdot 10^{-5}  |
### Table 1 (continued)

| Diseases (groups of diseases)/metabolic path-ways | ID       | C        | O        | E        | R        | adjP     |
|-------------------------------------------------|----------|----------|----------|----------|----------|----------|
| Intestinal Neoplasm                              | PA444635 | 268      | 29       | 11.25    | 2.58     | 0.0001   |
| Breast Neoplasms                                 | PA443560 | 377      | 35       | 15.82    | 2.21     | 0.0002   |
| Leukemia, Myeloid                                | PA444761 | 279      | 29       | 11.71    | 2.48     | 0.0002   |
| Lymphoma, T-Cell                                 | PA446309 | 167      | 21       | 7.01     | 3.00     | 0.0002   |
| Adenoma                                          | PA443269 | 157      | 20       | 6.59     | 3.04     | 0.0002   |
| Colorectal Neoplasms                             | PA446108 | 260      | 27       | 10.91    | 2.47     | 0.0003   |
| Neuroblastoma                                    | PA445100 | 229      | 25       | 9.61     | 2.60     | 0.0003   |
| Leukemia, Myeloid, Acute                         | PA444760 | 208      | 23       | 8.73     | 2.63     | 0.0004   |
| Neoplasm of unspecified nature of digestive system | PA165108442 | 445      | 38       | 18.68    | 2.03     | 0.0005   |
| Neoplasm Invasiveness                            | PA445057 | 298      | 29       | 12.51    | 2.32     | 0.0005   |
| Carcinoma, Renal Cell                            | PA443624 | 121      | 16       | 5.08     | 3.15     | 0.0007   |
| Neoplasm Metastasis                              | PA445058 | 315      | 29       | 13.22    | 2.19     | 0.0010   |
| **Other**                                        |          |          |          |          |          |          |
| Metabolic Diseases                               | PA444938 | 612      | 57       | 25.69    | 2.22     | 1.68 \( \times 10^{-5} \) |
| Immune System Diseases                           | PA444602 | 680      | 60       | 28.54    | 2.10     | 4.18 \( \times 10^{-6} \) |
| Endocrine System Diseases                        | PA444037 | 429      | 43       | 18.00    | 2.39     | 7.90 \( \times 10^{-6} \) |
| Diabetes Mellitus, Type 2                        | PA443890 | 254      | 31       | 10.66    | 2.91     | 7.07 \( \times 10^{-6} \) |
| Chromosome Aberrations                           | PA443728 | 371      | 39       | 15.57    | 2.50     | 8.33 \( \times 10^{-6} \) |
| Translocation, Genetic                           | PA445914 | 431      | 41       | 18.09    | 2.27     | 4.35 \( \times 10^{-5} \) |
| Chromosome Deletions                             | PA443729 | 343      | 36       | 14.40    | 2.50     | 2.18 \( \times 10^{-5} \) |
| Chromosomal Disorders                            | PA447160 | 418      | 41       | 17.54    | 2.34     | 2.18 \( \times 10^{-5} \) |
| Colonic Diseases                                 | PA443754 | 279      | 32       | 11.71    | 2.73     | 1.37 \( \times 10^{-5} \) |
| Inflammation                                     | PA444620 | 435      | 40       | 18.26    | 2.19     | 0.0001   |
| Viral Diseases                                    | PA446038 | 488      | 43       | 20.48    | 2.10     | 0.0001   |
| Autoimmune Diseases                              | PA443464 | 414      | 37       | 17.38    | 2.13     | 0.0003   |
| Gastrointestinal Diseases                        | PA444256 | 413      | 37       | 17.33    | 2.13     | 0.0003   |
| Lung Disease                                     | PA444814 | 354      | 33       | 14.86    | 2.22     | 0.0004   |
| Celiac Disease                                   | PA443652 | 153      | 19       | 6.42     | 2.96     | 0.0004   |
| Intestinal Diseases                              | PA444632 | 331      | 31       | 13.89    | 2.23     | 0.0005   |
| Infections                                       | PA444614 | 516      | 42       | 21.66    | 1.94     | 0.0006   |
| Heat Stress Disorders                            | PA446781 | 39       | 7        | 1.64     | 4.28     | 0.0079   |
| Loss of Heterozygosity                           | PA446859 | 342      | 24       | 14.35    | 1.67     | 0.0352   |
| **Metabolic pathways**                           |          |          |          |          |          |          |
| Pathways in cancer                               |           |          |          |          |          |          |
| Cytokine—cytokine receptor interaction           | 04060    | 265      | 30       | 11.12    | 2.70     | 2.83 \( \times 10^{-5} \) |
| Leukocyte transendothelial migration             | 04670    | 116      | 15       | 4.87     | 3.08     | 0.0016   |
| Wnt signaling pathway                            | 04310    | 150      | 17       | 6.30     | 2.70     | 0.0028   |
| Aldosterone-regulated sodium reabsorption        | 04960    | 42       | 8        | 1.76     | 4.54     | 0.0039   |
| Vascular smooth muscle contraction               | 04270    | 116      | 13       | 4.87     | 2.67     | 0.0075   |
| Glioma                                           | 05214    | 65       | 9        | 2.73     | 3.30     | 0.0085   |
| Amyotrophic lateral sclerosis                    | 05014    | 53       | 8        | 2.22     | 3.60     | 0.0088   |
Diseases (groups of diseases)/metabolic path-ways	ID	C	O	E	R	adjP

| Diseases (groups of diseases)/metabolic path-ways | ID   | C    | O    | E    | R    | adjP  |
|-------------------------------------------------|------|------|------|------|------|-------|
| Cell cycle                                      | 04110| 124  | 13   | 5.20 | 2.50 | 0.0111 |
| JAK-STAT signaling pathway                      | 04630| 155  | 15   | 6.51 | 2.31 | 0.0113 |
| Renal cell cancer                               | 05211| 70   | 9    | 2.94 | 3.06 | 0.0121 |
| Small cell lung cancer                          | 05222| 85   | 10   | 3.57 | 2.80 | 0.0123 |
| DNA replication                                 | 03030| 36   | 6    | 1.51 | 3.97 | 0.0142 |
| Systemic lupus erythematosus                    | 05322| 136  | 13   | 5.71 | 2.28 | 0.0174 |
| Insulin signaling pathway                       | 04910| 138  | 13   | 5.79 | 2.24 | 0.0191 |
| Basal cell carcinoma                            | 05217| 55   | 7    | 2.31 | 3.03 | 0.0255 |
| DNA mismatch repair                             | 03430| 23   | 4    | 0.97 | 4.14 | 0.0429 |
| Antigen processing and presentation             | 04612| 76   | 8    | 3.19 | 2.51 | 0.0429 |

Notes: *Analysis was conducted using the analytical internet resource Web-Gestalt [32, 33]. ID – identification number according to Disease database for diseases and the KEGG Pathway Database for metabolic pathways. The following design indicators were provided: C, the number of reference genes in the category; O and E, respectively, observed and expected number of genes in the category, the expression of which can potentially be regulated by miR 638; R = O/E, excessive representation of genes in an appropriate category in the tested selection ratio of enrichment); adjP, p value adjusted by the multiple test adjustment according to the Benjamini–Hochberg method.

important to the pathogenesis of a wide range of diseases. This proposition is confirmed herein by conducting clinical and experimental studies.

Clinical and experimental confirmation of the involvement of miR-638 in the pathogenesis of multifactorial diseases

Significant evidence was obtained regarding changes in the expression of miR-638 in different multifactorial diseases (Table 2). Changes in the level of expression of miR-638 in the tumor tissue of different organ systems (e. g., intestinal tract, breast, and lung) are recorded compared with normal tissue, and in the blood serum of patients with oncopathology, compared with healthy individuals. The majority of studies detected a reduction in the level of this microRNA in tumors and in the blood serum of patients. Contradictory results were obtained only for breast cancer, where two studies detected lower levels of miR-638 in tumor tissue [34, 35] and one study detected the reverse situation [36], where this can be linked to the clinical features of patients included in the study. Specifically, the level of expression of this microRNA was higher in patients with triple-negative breast cancer compared with that in patients with other forms of breast cancer [34]. It is also known that miR-638 expression can be affected by certain medications [11, 34].

Where patients had low levels of miR-638 in tumor tissue and blood serum prior to treatment, this was associated with a more unfavorable clinical presentation (large tumor size, later disease stage, and occurrence of metastases) [25, 26, 35, 40, 42–44], as well as negative survival forecasts (general and remote relapse free) [27, 35, 38, 40, 42, 43]. These situations were observed for tumors in different organ systems (Table 1) except for nasopharyngeal carcinoma, where a reduction in survival was demonstrated for people with higher levels of miR-638 [38].

Level of expression of miR-638 in different pathological conditions

| Pathology, source | Level of miR-638 and its value |
|-------------------|-------------------------------|
| Non-small cell lung cancer [11, 37] | Reduction of expression was observed in 68% of tumor tissues. For patients with increased levels of miR-638 in their blood serum after chemotherapy, longer survival was typical than for those with a reduction in levels of miR-638. At a high level of miR-638 expression in blood serum after chemotherapy, the risk of metastasis in lymphatic nodes was lower. |
| Nasopharyngeal carcinoma [38] | Individuals with a high level of miR-638 in their blood serum had poorer over-all survival and distant metastasis-free survival. |
### Table 2 (continued)

| Pathology, source                                                                 | Level of miR-638 and its value                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Stomach cancer [25, 26]                                                          | Level of miR-638 was lower in tumor tissue and in the cell lines of tumors than in adjacent normal tissues, and in normal lines of stomach epithelial cells. Low levels of miR-638 was linked to poor differentiation of tumors, tumor size, lymph node metastasis, and more severe stages of TNM. |
| Colon cancer [39]                                                                 | Level of miR-638 was significantly reduced in the serum exosomes of patients when compared with that of healthy individuals. The reduction was more obvious at the later stages of TNM and among patients with metastasis in the liver. At low levels of miR-638, lower overall and disease-free survival was registered. |
| Colorectal cancer [40]                                                            | The level of miR-638 was lower in the serum exosomes of patients than in healthy individuals. A lower level of miR-638 was associated with increased risk of liver metastasis and later TNM.                                                                                         |
| Colorectal cancer [27]                                                            | A lower level of miR-638 in tumor tissue than in noncancerous tissue. A low level of miR-638 in tumor tissue is linked with an unfavorable disease forecast.                                                                                |
| Hepatocellular carcinoma [41–43]                                                  | In the serum exosomes, in tumor tissue (as well as in cell lines), miR-638 level was lower than in the serum of healthy individuals and normal liver tissue. Low levels miR-638 is associated with tumor size, metastasis, vascular invasion, later TNM stage, and low postoperative survival. |
| Cervical cancer [44]                                                              | Expression of miR-638 was lower in cancer-invaded tissue (cell lines) in comparison with that in normal tissue (cell lines). Low expression was associated with later stages, as per the International Federation of Gynecology and Obstetrics (FIGO) classification, with metastasis in lymphatic nodes, vascular invasion, and low overall and progression-free survival. |
| Breast cancer [35]                                                                | In tumor tissue (cell lines), lower levels of miR-638 expression was in compared with those in normal tissue (cell lines). Low expression correlated with lymph node metastasis and later stages as per TNM, with shorter overall survival. |
| Invasive ductal carcinoma [34]                                                    | In tumor tissue samples, miR-638 expression was lower than that in normal tissue. Low miR-638 levels were more often registered in patients with non-basal-like breast cancer, compared with that in patients with a diagnosis of triple-negative breast cancer. |
| Breast cancer and esophageal squamous cell carcinoma [36]                        | Higher miR-638 expression in tumor tissue than in normal tissue.                                                                                                                                                          |
| Osteosarcoma [45]                                                                | In osteosarcoma tissue, miR-638 level was reduced compared with that healthy tissue. Ectopic expression of miR-638 inhibited cell growth of osteosarcoma in vitro.                                                                    |
| Ewing sarcoma [46]                                                               | miR-638 was significantly down-regulated in tumor cells. Overexpression of miR-638 suppressed cell growth, induced cell apoptosis, and inhibited tubule formation in vitro.                                                                 |
| Glioma [47]                                                                      | Experimental studies show inhibition of miR-638 restore proliferation and invasion of glioma cells.                                                                                                                        |
| Stenosis of carotid arteries [48]                                                 | Compared with that for individuals without carotid artery atherosclerosis, the level of miR-638 in blood serum was significantly lower for patients with carotid artery stenosis undergone carotid endarterectomy, particularly in the sub-group patients who had experienced stroke. Lower levels were registered in individuals experiencing an impact on both carotid arteries, stroke, coronary artery disease, high risk of fibroatheroma, and among smokers. |
| Behcet’s disease [49]                                                             | Level of miR-638 in blood mononuclear were reduced in patients with in comparison with healthy controls.                                                                                                                  |
| COPD of smokers [50]                                                             | A higher level of miR-638 expression was observed in lung tissue at severe invasion areas.                                                                                                                                  |
| Polycystic ovary syndrome [51]                                                    | Increased level of circulated miR-638 among patients compared with that among healthy women.                                                                                                                              |
| Celiac disease [52]                                                              | In the duodenal mucosa of patients with celiac disease that exhibited classic clinical symptoms, and with hypoferric anemia following a gluten-free diet, the level of miR-638 was higher than that in individuals with normal duodenal mucous. The level of miR-638 was higher in patients with hypoferric anemia, compared with that in those with classic symptoms of celiac disease. |
| Sporadic amyotrophic lateral sclerosis [53]                                       | Increased level of miR-638 expression in samples of leucocytes among patients compared with among those without pathology.                                                                                                    |
| Systemic sclerosis [54]                                                          | Increased level of circulating miR-638. Level of miR-638 was slightly reduced in an anti-Scl-70-positive group of patients compared with that in an anti-Scl-70-negative group.                                                              |
One of the mechanisms that regulates the expression of microRNA is the methylation of its gene promoter. Hypermethylation of the host gene of miR-638 (DNM2) was registered in colorectal cancer tissue [62]. Zhang et al. demonstrated that the CpG island in the area of the miR-638 promoter in colorectal cancer tissue was hypermethylated. Therefore, a lower level of this microRNA expression was observed, and weakening of the methylation level was sufficient for the recovery of miR-638 expression in tumor cells [27]. When miR-638 expression increased, inhibition of proliferation was observed, as well as the invasion of cancer cells and arrest of the cell cycle in the G1 phase, whereas repression of miR-638 resulted in contrasting effects [27]. Similar results were obtained in experimental studies by other authors [25, 35, 42, 45–47]. This explains a more favorable forecast for patients who had increased levels of miR-638 following treatment. For example, patients with non-small lung cancer cells after cisplatin chemotherapy showed an increase in serum miR-638, longer survival than had patients with a reduced level of this microRNA [37]. The high level of expression of miR-638 stipulated an elevated sensitivity of tumor cells to cisplatin, which ultimately resulted in a reduction of the tumor cells’ viability in response to chemotherapy [63]. The same authors determined that high expression of miR-638 affected the recovery processes of damaged DNA by means of suppressing the expression of γH2AX [63]. miR-638 also reduced the ability of repair DNA damage in triple-negative breast cancer cells that had been impacted by ultraviolet irradiation and cisplatin [34]. These conflicting results indicate the different physiological effects of microRNA (miR-638 in particular) under different conditions.

The fact that in the majority of cases, a lower level of miR-638 was registered in tumor cells compared with normal cells, allows microRNA to be considered as a tumor suppressor (e.g., for Ewing’s sarcoma, cervical cancer, breast cancer, and stomach cancer) [25, 27, 35, 44–46] and as an independent prognostic factor for different oncological diseases (regardless of the disease stage TNM and occurrence of metastases) [27]. However, single studies will be noted herein in which miR-638 served as an oncogene contributing to cell proliferation, migration, and invasion (for esophageal squamous cell cancer and breast cancer) [36]. According to the analysis of enrichment (Table 1), changes in the expression in oncological diseases are significantly correlated with data related to an excess of genes regulated by miR-638, among genes associated with pathologies and metabolic pathways.

Low expression of miR-638 in blood serum or affected tissue has been registered for other diseases such as atherosclerosis of the carotid artery, Behcet’s disease, hypertension, and nephrotic syndrome (Table 2). Interestingly, patients with cardiovascular disease, as in the case of those with oncological disease, demonstrated lower levels of miR-638. Furthermore, much lower levels of this microRNA were typical for patients with severe clinical presentation [48]. One study determined that the level of this microRNA was lower in smokers compared with that in non-smokers, which correlates with data regarding an increase in the level of methylation of the CpG sites of this miR-638 for smokers [10]. It is known that miR-638 is highly expressed in smooth muscle cells of human aorta and is involved in the regulation of proliferation and migration in these

| Pathology, source | Level of miR-638 and its value |
|------------------|------------------------------|
| Lupus nephritis [55] | Compared with that in control samples, lupus nephritis patients had lower glomerular expression of miR-638, but higher tubulo-interstitial expression of this microRNA Tubulo-interstitial miR-638 expression was significantly correlated with proteinuria and disease activity score |
| Lupus nephritis [56] | In liver biopsy slides of patients, the level of miR-638 was higher than that in control samples |
| Lupus nephritis [57] | In peripheral blood mononuclear cell lines obtained from patients with lupus nephritis, the expression of miR-638 was higher than in control samples (shown for Caucasians and African Americans) |
| Nephropathy at DM2 [58] | Patients with diabetic nephropathy had higher levels of miR-638 in urine exosomes than had patients with DM2 without nephropathy and healthy individuals |
| Nephrotic syndrome [59] | In healthy individuals, the level of miR-638 in urine was significantly lower than that in patients with different types of nephrotic syndromes (diabetic glomerulosclerosis, nephropathy with minimal disorders, focal glomerulosclerosis, and membrand nephropathy) |
| Hypertension [60] | Level of miR-638 in the renal medulla of patients with hypertension was lower compared with those with normal arterial pressure |
| Age-related cataracts [61] | miR-638 was included in the top 10 expressed microRNAs in the normal human eye lens, but not in lenses affected by cataracts |

Notes. COPD, chronic obstructive pulmonary disease; DM2, diabetes mellitus type 2; FIGO, International Federation of Gynecology and Obstetrics; TNM (Tumor, Nodus, and Metastasis), international classification of stages of a malignant tumor.
cells [64]. This microRNA also affects the proliferation and migration of smooth muscle cells in the respiratory tract (hyper-expression inhibits proliferation and migration), which indicates the potential of miR-638 in asthma pathogenesis [17].

For the above-noted diseases, miR-638 is considered a diagnostic marker, as well as a therapeutic target. The level of miR-638 in blood serum is proposed for use as an invasive biomarker for plaque vulnerability and the probability of ischemic stroke, particularly among individuals at risk of cardiovascular complications [48]. It has been stated that changing the level of miR-638 in vascular smooth muscle cells may be useful in the treatment of proliferative vascular diseases [64]. miR-638 can also serve as a new therapeutic target for the prevention of hyperplasia of smooth muscle cells in the respiratory tract in asthma [17].

A reduction in the expression of miR-638 was not observed for all pathologies. A number of diseases demonstrated an increase in the level of this microRNA in the blood serum of patients or in affected tissue (Table 2). This situation was detected for esophageal squamous cell cancer, polycystic ovary syndrome, and celiac disease. For example, an increase in the expression of miR-638 was registered in the blood serum of patients with sporadic amyotrophic lateral sclerosis [53]. However, contradictory results have been obtained for this disease in different studies [53]. Development of this disease can be promoted by a wide range of environmental factors (e.g., heavy metals, pesticides, smoking, and viral infections) [65]. Accordingly, conflicting results from different studies regarding changes in the expression of miR-638 in the case of amyotrophic lateral sclerosis can be explained in a number of ways. On the one hand, sporadic amyotrophic lateral sclerosis can differ on the basis of etiological factors. On the other hand, the focus of changes to the level of this microRNA can differ in response to exogenous stimulants. Specifically, it was demonstrated that infectious agents can result in an increase in the expression of miR-638 [12, 16, 17]. This means that the same pathological phenotype can result from different pathophysiological pathways, which can be explained by the presence of different genetic components (genes and their structural and functional features), even in the presence of the common intermediate between environmental factors and genes (e.g., microRNA).

During comparison of miR-638 expression in the samples of affected tissues, a number of cases indicated conflicting results, which can be explained by tissue-specific differences. Lu et al. [55] determined bidirectional changes in the level of miR-638 in different areas of the kidney among patients with lupus nephritis (i.e., low levels in glomeruli and higher levels in tubulointerstitial tissue) compared with control samples (Table 2). However, two other studies detected an increase in the level of this microRNA in patients with lupus nephritis (in kidney biopsies and in peripheral blood mononuclear cells) [56, 57].

A change in the level of miR-638 during pathologies also influenced a change in the expression level of a number of proteins. For example, it was shown that a change in miR-638 expression had an effect: with Ewing sarcoma at the level of VEGFA protein [46], with osteosarcoma at the level of proto-oncogen PIM1 [45], with hepatocellular carcinoma and gastric cancer at the level of transcription factor SOX2 [22, 43], in colorectal carcinoma at the level of the cell surface protein TSPAN1 [27], in gastric cancer at the level of the methyl-CpG-binding protein 2 [26], in breast cancer at the level of BRCA1 [34], and in emphysema at the level of TOMM40 [50]. This microRNA also affected the expression of CCND1 (G1/S-specific cyclin-D1) and transcriptional activator NR4A3 (NOR1), which are required for cell proliferation, migration [17], and activation of the Wnt/β-catenin signaling pathway [44], disturbances to which can result in the formation of different pathologies including oncological diseases, metabolic and neurodegenerative disorders, and cardiovascular and endocrine system diseases. Individuals with hypertension demonstrated a reduction in the level of miR-638 in kidney tissue, and an increase in the expression of NR4A3 and RENBP when compared with individuals with normal arterial pressure [60]. According to TargetScanHuman, all genes coding the above-mentioned proteins had targets for miR-638. However, the range of genes regulated by miR-638 may be more widespread than forecasted by bioinformatic methods [50, 60].

The sensitivity of microRNA to environmental effects and the control of the expression of protein-coding genes may depend on the genetic features of the individual. Genetic polymorphic variants (SNP) in the microRNA binding sites can change the expression of genes regulated by appropriate miRNA.

So, on the one hand, the prevalence of allelic frequencies for rs799917 of the BRCA1 gene and rs334348 of the TGFR1 gene is significantly different among populations with different risks of developing breast cancer, and on the other, depending on the genetic characteristics of tumor cells according to the above polymorphic variants specificity in the regulatory potential of miR-638 and miR-628-5p for the BRCA1 and TGFR1 genes has been established [66].

Genetic variants in microRNA genes (particularly in the areas of target binding) can impact the expression of target genes. MIR638 gene includes a large number of polymorphic variants (SNP, insertions, and deletions, though low level of the polymorphisms are typical) [29], which can also modify the regulatory potential of this microRNA.
Genetic components are also involved in the regulation of DNA methylation. For example, one study demonstrated that smoking affected methylation in some areas of DNA in the blood leucocytes of native Hawaiians, but this was not the case in Europeans, Japanese, or Americans [67]. DNA methylation in fat tissue depended on the SNP associated with smoking [68], and etc. It was shown that DNA methylation was affected by exogenous and endogenous factors (in particular, smoking and obesity), as well as additive genetic factors [69]. This indicates the importance to take into account the genetic characteristics of the examined individuals during analysis of different epigenetic aspects (e.g., DNA methylation and the regulatory potential of microRNA).

The data presented in this review allow miR-638 to be considered as a sensitive to environmental effects marker that is in a wide range of diseases of a multifactorial nature. First, overlap was observed between diseases/groups of pathologies and metabolic pathways for which the potential target genes of microRNA were present in abundance (Table 1) and for the list of diseases where a change in the level of microRNA was detected in the affected tissue or blood serum of patients during clinical studies (Table 2). Second, data were accumulated to demonstrate that biotic and abiotic factors in the environment (including those serving as risk factors for multifactorial diseases) can affect the level of expression of miR-638. One of the mechanisms by which the level of expression of this microRNA can be changed is the methylation of CpG sites. Third, a number of cases showed that the level of miR-638 can affect expression and protein levels. The information provided in this review expands our perceptions on the pathogenesis of different multifactorial diseases and can help to determine new examination strategies for gene–environment interactions.

REFERENCES

1. Baranov V.S., Baranova E.V. Геном человека, эпигенетика многофакторных болезней и персонифицированная медицина // Биосфера. — 2012. — Т. 4. — № 1. — С. 76–85. [Baranov VS, Baranova EV. Human genome, epigenetics of complex diseases, and personalized medicine. Biosfera. 2012;4(1):76-85. (In Russ.)]

2. Паткин Е.Л., Софронов Г.А. Эпигенетика популяций, экотоксикогенетика и болезни человека // Экологическая генетика. — 2012. — Т. 10. — № 4. — С. 14–28. [Patkin EL, Sofiarov GA. Population epigenetics, ecotoxicology and diseases. Ecological Genetics. 2012;10(4):14-28. (In Russ.)]

3. Ахмадишина Л.З., Корытина Г.Ф., Кочетова О.В., Викторова Т.В. Аналит ген (CYP1A2, CYP2F1, NQO1, UGT2B7, CAT, GSTP1) средовых взаимодействий при профессиональном хроническом бронхите // Экологическая генетика. — 2014. — Т. 12. — № 2. — С. 47–59. [Akhmadishina LZ, Korytina GF, Kochetova OV, Viktorova TV. Genes (CYP1A2, CYP2F1, NQO1, UGT2B7, CAT, GSTP1) environment interactions in occupational chronic bronchitis. Ecological Genetics. 2014;12(2):47-59. (In Russ.)]. https://doi.org/10.17816/ecogen12247-59.

4. Davis FM, Gallagher KA. Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. Arterioscler Thromb Vasc Biol. 2019;39(4):623-634. https://doi.org/10.1161/ATVBAHA.118.312135.

5. Rohde K, Keller M, La Cour Poulsen L, et al. Genetics and epigenetics in obesity. Metabolism. 2019;92:37-50. https://doi.org/10.1016/j.metabol.2018.10.007.

6. Guida F, Sandanger TM, Castagné R, et al. Dynamics of smoking-induced genome-wide methylation changes with time since smoking cessation. Hum Mol Genet. 2015;24(8):2349-2359. https://doi.org/10.1093/hmg/ddu751.

7. Joubert BR, Felix JF, Yousefi P, et al. DNA Methylation in newborns and maternal smoking in pregnancy: genome-wide consortium meta-analysis. Am J Hum Genet. 2016;98(4):680-696. https://doi.org/10.1016/j.ajhg.2016.02.019.

8. De Vries M, van der Ploeg DA, Nedeljkovic I, et al. From blood to lung tissue: effect of cigarette smoke on DNA methylation and lung function. Respir Res. 2018;19(1):212. https://doi.org/10.1186/s12931-018-0904-y.

9. Siemelink MA, van der Laan SW, Haitjema S, et al. Smoking is associated to DNA methylation in atherosclerotic carotid lesions. Circ Genom Precis Med. 2018;11(9):e002030. https://doi.org/10.1161/CIRC.117.002030.

10. Кучер А.Н., Назаренко М.С., Марков А.В., и др. Вариабельность профилей метилирования CpG-сайтов генов микроРНК в лейкоцитах и тканях сосудов при атеросклерозе у человека // Биохимия. — 2017. — Т. 82. — № 6. — С. 923–933. [Kucher AN, Nazarenko MS, Markov AV, et al. Variability of methylation profiles of CpG sites in microRNA genes in leukocytes and vascular tissues of patients with atherosclerosis. Biochemistry (Moscow). 2017;82(6):698-706. (In Russ.)]. https://doi.org/10.1134/S0006297917060062.

11. Li D, Wang Q, Liu C, et al. aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci. 2012;125(2):382-391. https://doi.org/10.1093/toxsci/kfr299.

12. Saxena T, Tandon B, Sharma S, et al. Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells. PLoS One. 2013;8(11):e79886. https://doi.org/10.1371/journal.pone.0079886.
13. Liu Y, Chen X, Bian Q, et al. Analysis of plasma microRNA expression profiles in a Chinese population occupationally exposed to benzene and in a population with chronic benzene poisoning. *J Thorac Dis*. 2016;8(3):403-14. https://doi.org/10.21037/jtd.2016.02.56.

14. Liu X, Wang T, Wakita T, Yang W. Systematic identification of miRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. *Virolology*. 2010;389(1):57-67. https://doi.org/10.1016/j.virol.2009.11.036.

15. Sturchio E, Colombo T, Boccia P, et al. Arsenic exposure triggers a shift in microRNA expression. *Sci Total Environ.* 2014;472(528):672-680. https://doi.org/10.1016/j.scitotenv.2013.11.092.

16. Xun M, Ma CF, Du QL, et al. Differential expression of miRNAs in enterovirus 71-infected cells. *Virol J.* 2015;12(1):56. https://doi.org/10.1186/s12985-015-0288-2.

17. Wang H, Yao H, Yi B, et al. MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1. *J Cell Physiol.* 2018;234(1):369-381. https://doi.org/10.1002/jcp.26930.

18. Li X, Shi Y, Wei Y, et al. Altered expression profiles of microRNAs upon arsenic exposure of human umbilical vein endothelial cells. *Environ Toxicol Pharmacol.* 2012;34(2):381-387. https://doi.org/10.1016/j.etap.2012.05.003.

19. Zhang X, Chen C, Wu M, et al. Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients. *Antivir Ther.* 2012;17(7):1243-1253. https://doi.org/10.3851/IMP2401.

20. Kumar M, Sharma Y, Bandi S, Gupta S. Endogenous antiviral microRNAs determine permissiveness for hepatitis B virus replication in cultured human fetal and adult hepatocytes. *J Med Virol.* 2015;87(7):1168-1183. https://doi.org/10.1002/jmv.24145.

21. Wan Y, Cui R, Gu J, et al. Identification of four oxidative stress-responsive microRNAs, miR-34a-5p, miR-1915-3p, miR-638, and miR-150-3p, in hepatocellular carcinoma. *Oxid Med Cell Longev.* 2017;2017:5189138. https://doi.org/10.1155/2017/5189138.

22. Naraballobh W, Trakooljul N, Murani E, et al. miRNAs regulate acute transcriptional changes in broiler embryos in response to modification of incubation temperature. *Sci Rep.* 2018;8(1):11371. https://doi.org/10.1038/s41598-018-29316-7.

23. Bastian FB, Parmentier G, Roux J, et al. Bgee: integrating and comparing heterogeneous transcriptome data among species. 2008;5109:124-131 [Internet]. In: Bairoch A, Cohen Boulakia S, Froidevaux C. DILS: data integration in life sciences. 5th International Workshop, DILS2008, Evry, France, June 25-27, 2008. Available from: https://bgee.org/?page=about.

24. Genevisible. TOP 10 CANCERS [Internet]. Nebion AG, Zurich, Switzerland; 2016. Available from: https://genevisible.com/cancers/HS/UniProt/P05570.

25. Shen Y, Chen H, Gao L, et al. MiR-638 acts as a tumor suppressor gene in gastric cancer. *Oncotarget.* 2017;8(64):108170-108180. https://doi.org/10.18632/oncotarget.22567.

26. Zhao LY, Tong DD, Xue M, et al. McCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1. *Oncogenesis*. 2017;6(7):e368. https://doi.org/10.1038/oncsis.2017.60.

27. Zhang J, Fei B, Wang Q, et al. MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. *Oncotarget.* 2014;5(23):12083-12096.

28. NCBI. Gene [Internet]. Available from: https://www.ncbi.nlm.nih.gov/gene/.

29. EMBL-EBI. Ensembl Release 97 [cited July 2019]. Available from: https://www.ensembl.org.

30. TargetScanHuman. Search for predicted microRNA targets in mammals [cited March 2018]. Available from: http://www.targetscan.org/vert_72/.

31. Agarwal V, Bell GW, Nam J, Bartel DP. Predicting effective microRNA target sites in mammalian miRNAs. *Elife*. 2015;4: e05005. https://doi.org/10.7554/eLife.05005.

32. WebGestalt. WEB-based GEne SeT AnaLysis Toolkit [cited 05/22/2019]. Available from: http://www.webgestalt.org/option.php.

33. Wang J, Duncan D, Shi Z, et al. WEB-based GEnE SeT AnaLysis Toolkit (WebGestalt): update 2013. *Nucleic Acids Res.* 2013;41(Web Server issue): W77-83. https://doi.org/10.1093/nar/gkt439.

34. Tan X, Peng J, Fu Y, et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. *Breast Cancer Res.* 2014;16(5):435. https://doi.org/10.1186/s13058-014-0435-5.

35. Li M, Wang J, Liu H. Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients. *Onco Targets Ther.* 2018;11:6871-7. https://doi.org/10.2147/OTT. S182034.

36. Ren Y, Chen Y, Liang X, et al. MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3. *Cancer Lett.* 2017;390:126-36. https://doi.org/10.1016/j.canlet.2017.01.009.

37. Wang F, Lou JF, Cao Y, et al. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. *Exp Mol Med.* 2015;47:e162. https://doi.org/10.1038/emm.2015.17.

38. Liu N, Cui RX, Sun Y, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carci-
39. Yan S, Deng G, Zhang X, et al. Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients. *Oncotarget*. 2017;8(42):72220-72226. https://doi.org/10.18632/oncotarget.19689.

40. Yan S, Han B, Gao S, et al. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. *Oncotarget*. 2017;8(36):60149-60158. https://doi.org/10.18632/oncotarget.18557.

41. Cheng J, Chen Y, Zhao P, et al. Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance. *Oncol Lett*. 2017;13(5):3859-3865. https://doi.org/10.3892/ol.2017.5882.

42. Shi M, Jiang Y, Yang L, et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. *J Cell Biochem*. 2018;119(6):4711-6. https://doi.org/10.1002/jcb.26650.

43. Ye W, Li J, Fang G, et al. Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma: Association between clinicopathological features and prognosis. *Oncol Lett*. 2018;15(3):7255-7264. https://doi.org/10.3892/ol.2018.8208.

44. Wei H, Zhang JJ, Tang QL. MiR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients. *Eur Rev Med Pharmacol Sci*. 2017;21(24):5587-5593. https://doi.org/10.26355/eurrev_201712_13999.

45. Wang XX, Liu J, Tang YM, et al. MicroRNA-638 inhibits cell proliferation by targeting suppress PIM1 expression in human osteosarcoma. *Tumour Biol*. 2017. https://doi.org/10.1007/s13277-016-5379-1.

46. Zhou X, Chen J, Xiao Q, et al. MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. *Biosci Rep*. 2018;38(1). pii:BSR20171017. https://doi.org/10.1042/BSR20171017.

47. Chen Z, Duan X. hsa_circ_0000177-miR-638-FZD7-Wnt signaling cascade contributes to the malignant behaviors in glioma. *DNA Cell Biol*. 2018;37(9):791-797. https://doi.org/10.1089/dna.2018.4294.

48. Luque A, Farwati A, Krupinski J, Aran JM. Association between low levels of serum miR-638 and atherosclerotic plaque vulnerability in patients with high-grade carotid stenosis. *J Neurosurg*. 2018;1:8. https://doi.org/10.3171/2018.2.JNS171899.

49. Woo MY, Yun SJ, Cho O, et al. MicroRNAs differentially expressed in Behçet disease are involved in interleukin-6 production. *J Inflamm (Lond)*. 2016;13:22. https://doi.org/10.1186/s12950-016-0130-7.

50. Christenson SA, Brandsma CA, Campbell JD, et al. miR-638 regulates gene expression networks associated with emphysematous lung destruction. *Genome Med*. 2013;5(12):114. https://doi.org/10.1186/gm519.
in terminally differentiated cells. *Aging (Albany NY).* 2016;8(7):1442-1456. https://doi.org/10.18632/aging.100998.

64. Li P, Liu Y, Yi B, et al. MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. *Cardiovasc Res.* 2013;99(1):185-193. https://doi.org/10.1093/cvr/cvt082.

65. Zuliria M, Gil-Bea FJ, Fernández-Torrón R, et al. ALS: a bucket of genes, environment, metabolism and unknown ingredients. *Prog Neurobiol.* 2016;142:104-129. https://doi.org/10.1016/j.pneurobio.2016.05.004.

66. Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. *Cancer Res.* 2010;70(7):2789-2798. https://doi.org/10.1158/0008-5472.CAN-09-3541.

67. Park SL, Patel YM, Loo LW, et al. Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. *Clin Epigenetics.* 2018;10(1):110. https://doi.org/10.1186/s13148-018-0543-7.

68. Tsai PC, Glastonbury CA, Elliot MN, et al. Smoking induces coordinated DNA methylation and gene expression changes in adipose tissue with consequences for metabolic health. *Clin Epigenetics.* 2018;10(1):126. https://doi.org/10.1186/s13148-018-0558-0.

69. Hannon E, Knox O, Sugden K, et al. Characterizing genetic and environmental influences on variable DNA methylation using monozygotic and dizygotic twins. *PLoS Genet.* 2018;14(8):e1007544. https://doi.org/10.1371/journal.pgen.1007544.